malignant lymphoma
Conditions
Interventions
For PET-negative patients after 4 courses of chemotherapy: end of treatment
For PET-positive patients after 4 courses of chemotherapy: 30 Gy Involved Node
Radiotherapy
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Histologically proven Hodgkin lymphoma * Newly diagnosed, no previous treatment * Stage I, IIA with RF a-d; stage IIB with RF c, d (a: large mediastinal mass, b: extranodal disease, c: high ESR, d: * 3 lymph node areas) * Age: 18-60 years * Patient had no previous treatment for HL * Normal organ function (except HL-related); * Life expectancy > 3 months.
Exclusion criteria
Exclusion criteria: * Composite lymphoma * Previous malignancy, prior chemotherapy or radiotherapy * Concurrent diseases which preclude protocol treatment * Pregnancy, lactation * Non-compliance * WHO activity index > 2 * Antiepileptic treatment * Concurrent diseases which preclude protocol treatment * Long-term administration of corticosteroids (e.g. for chronic polyarthritis) or antineoplastic drugs (e.g. azathioprine, methotrexate)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| - CR rate - Overall survival (OS) - Proportion of patients with good / inadequate response to 2 cycles of escalated BEACOPP and 2 cycles of ABVD - Late toxicities of treatment - Secondary malignancies | — |
Countries
Netherlands
Outcome results
None listed